The US innovation-based industry association, Pharmaceutical Research Manufacturers of America (PhRMA), has again called on Japan to reform its unpredictable and frequent reimbursement price-cutting policies for prescription drugs and to direct more funding and support to innovation in the national biopharma industry.
PhRMA's Narasimhan Asks Japan To Reform Pricing Policies
Phase I Waiver Plan 'Very Positive'
Pointing to what it says is decreased R&D in Japan in contrast to the global market, PhRMA has again urged the country to revise its drug pricing policies and support innovation, while cautiously welcoming new moves to waive a requirement for Phase I trials in the country.